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Abstract
Anxiety and depressive disorders are common in the pediatric primary care setting, and respond to 
both psychotherapeutic and antidepressant pharmacotherapy treatment. However, there are limited 
data regarding the optimal treatment duration. This paper systematically reviews guidelines and 
clinical trial data related to antidepressant treatment duration in pediatric depressive and anxiety 
disorders. The extant literature suggests 9–12 months of SSRI treatment for youth with major 
depressive disorder. For generalized, separation and social anxiety disorders, 6–9 months of SSRI 
treatment may be sufficient, though many clinicians extend treatment to 12 months based on 
extrapolation of data from adults with anxiety disorders. Such extended treatment periods may 
decrease the risk of long-term morbidity and recurrence; however, the goal of treatment is 
ultimately remission, rather than duration of antidepressant pharmacotherapy. Evidence-based 
guidelines represent a starting point; however, appropriate treatment duration varies and patient-
specific response, psychological factors, and timing of discontinuation must be considered for 
individual pediatric patients.
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INTRODUCTION
Anxiety and depressive disorders are common in the pediatric primary care setting and affect 
10% of children and adolescents.1 Successful treatment of depressive and anxiety disorders 
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in youth—whether psychotherapeutic or psychopharmacologic—should restore function, 
establish remission and decrease the likelihood of relapse and recurrence. With successful 
treatment, however, the following questions frequently arise in clinical care: How long 
should this patient be treated with an antidepressant? When can the antidepressant that I’ve 
started be discontinued? Will the treatment gains be sustained upon discontinuation of the 
patient’s antidepressant medication? If the patient cannot come off medication what is the 
next best solution?
To inform best practices for determining duration of antidepressant treatment, we 
systematically reviewed: (1) current practice guidelines for antidepressant treatment 
duration; (2) evidence for optimal duration of antidepressant treatment and (3) specific 
psychotherapeutic and psychopharmacologic strategies for preventing relapse.
BACKGROUND
Anxiety and depression are associated with substantial morbidity, including impaired social 
and academic functioning and increase the risk of suicide and suicide attempts2. Anxiety and 
depression both respond to psychotherapeutic and psychopharmacologic interventions. 
However, in some pediatric primary care settings these disorders may be under-recognized 
and untreated.3 Data have accumulated during the last several decades that support 
symptomatic and functional improvement with the use of psychotherapy4,5 and selective 
serotonin reuptake inhibitors (SSRIs),6–8 particularly fluoxetine9–11 for the treatment of 
depressive and anxiety disorders in youth.4,12–14 Despite the efficacy of these interventions 
in short-term treatment studies, the risk of relapse and recurrence remains high, with five-
year recurrence rates of up to 70% and 50% in children and adolescents with major 
depressive disorder or anxiety disorders, respectively.15,16
In adults with affective and anxiety disorders, common strategies to prevent recurrence 
include: (1) continuation of acute treatment; (2) utilization of psychotherapy booster 
sessions to prolong response; and (3) implementation of uniquely tailored recurrence 
prevention interventions.17 However, the evidence for these interventions is limited in the 
pediatric population and these limitations are compounded by the short duration of many 
acute psychopharmacologic treatment studies, that often describe acute response over ≤12 
weeks.4,9,13,14,18,19 These studies were primarily aimed at establishing the efficacy and 
determining the safety profile of antidepressants in the short-term; but, data regarding the 
impact on longer-term outcomes associated with these interventions are limited.
Major Depressive Disorder (MDD): Current Guidelines
Acute Treatment Guidelines for Pediatric MDD—Current treatment guidelines focus 
on the acute treatment of MDD in pediatric patients. Generally, for moderate to severe 
illness, these guidelines recommend treatment with a combination of an evidence-based 
psychotherapy and an SSRI.20–22 SSRIs have the most favorable risk-benefit profile as a 
first-line medication, with assessment of response every four weeks and dose titration when 
partial response is encountered. While symptom remission should occur in many studies by 
twelve weeks of psychopharmacologic treatment, there are conflicting recommendations for 
the duration of treatment following depression in pediatric patients. The GLAD-PC 
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guidelines23 recommend “medications should be maintained for 6–12 months after the full 
resolution of depressive symptoms.” Similarly, the American Academy of Child & 
Adolescent Psychiatry (AACAP) Practice Parameters recommend continuation of treatment 
for 6–12 months “for all patients who have responded to the acute treatment.”24 Further, 
these parameters suggest that summer may be a preferred period for antidepressant 
discontinuation and suggest that longer treatment may be recommended for some 
individuals, particularly for those with risk factors such as multiple past episodes, comorbid 
disorders, or socio-environmental concerns.24
The Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Guidelines for 
MDD recommend that maintenance treatment for 6–12 months in youth without a history of 
MDD prior to the index episode and recommend >1 year of treatment for youth with a prior 
history of >2 depressive episodes or 1 “severe or chronic episode.”25 These guidelines note 
that the evidence for these recommendations is limited. Additionally, multiple studies have 
evaluated longer-term treatment since the publication of GLAD-PC23 and AACAP Practice 
Parameters.
Relapse and Remission in Youth with MDD—While the medical vernacular is replete 
with references to “relapse” and “remission,” there is considerable variability in its 
application to depression. Relapse is defined as a Diagnostic and Statistical Manual of 
Mental Disorders-defined depressive episode during a remission period, with remission 
being a period of no or few depressive symptoms for ≥2 weeks but <2 months.26 Recurrence 
represents the onset of a new depressive episode during a recovery period, with recovery 
being the absence of significant depressive symptoms for at least two months26 (Figure 1). 
Defining relapse and recurrence in adolescents is complicated by fluctuations in affective 
symptoms whether related to developmental factors or the underlying internalizing disorder.
17,27
Controlled Medication Trials in Youth with MDD: Duration of Treatment Effects
Long-term Outcomes in the Treatment for Adolescents with Depression Study 
(TADS)—The Treatment for Adolescents with Depression Study (TADS) evaluated the 
acute efficacy of: (1) fluoxetine (monotherapy), (2) CBT (monotherapy), (3) fluoxetine + 
CBT, and (4) placebo in adolescents with MDD.11 During the initial 12-week treatment 
phase both fluoxetine monotherapy and fluoxetine+CBT resulted in higher response rates 
compared to CBT alone.28 During the extension phase, by week 18, response rates to CBT 
(65%) were comparable to fluoxetine (69%), but fluoxetine+CBT resulted in a response rate 
of 85%.11 In addition, combined treatment resulted in a more rapid effect, but by week 36 
comparable response rates (81–86%) were observed.29 Taken together, the results of this 
study suggest a benefit to longer treatment duration, with remission rates for treated patients 
increasing from 23% at week 12 to 60% at week 36.29 The proportion of patients who 
experienced a sustained response (not necessarily remission) improved similarly, across 
treatment conditions but sustained response was more likely to be maintained through week 
36 if the acute treatment included CBT.29
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TADS11 included 1-year of naturalistic follow up, after the 36 week treatment period, with 
assessments at 3, 6, 9, and 12 months 30. Response rates and suicidality did not differ among 
the treatments at 12 months, although patients treated with CBT + fluoxetine “generally 
maintained numerical superiority relative to CBT and fluoxetine [monotherapies].”30 
Symptomatic recurrence varied by acute treatment type but generally occurred in fewer than 
one third of participants during the 12 months following acute treatment.30 This is a lower 
rate than reported in many other relapse studies.16
Finally, the Survey of Outcomes Following Treatment for Adolescent Depression 
(SOFTAD) study31 evaluated nearly half (45%) of TADS participants at six-month intervals 
for the 3½ years following the initial 12 month acute/naturalistic treatment. During this 
period, 96% of patients recovered from their index major depressive episode. Recovery, by 
two years, was significantly more likely for those who responded to acute treatment. 
However, 47% of patients who recovered experienced a recurrence during the SOFTAD 
study period, with recurrence significantly more common in females (57% [females], versus 
32.9% [males]). Last, recurrence rates did not differ among acute treatments in TADS.31
Long-Term Outcomes in the Treatment of SSRI-Resistant Depression in 
Adolescents (TORDIA) Study—The Treatment of SSRI-Resistant Depression in 
Adolescents (TORDIA) Study evaluated (1) switching to another SSRI, (2) switching to 
another SSRI and adding CBT, (3) switching to venlafaxine, or (4) switching to venlafaxine 
and adding CBT in adolescents (N=334) who failed to respond to an adequate initial SSRI 
treatment. Greater improvement was observed with the addition to CBT to either a new 
SSRI or SNRI.32 Following acute treatment (12 weeks), responders continued to receive 
their previously assigned treatment for an additional 12 weeks, while those who failed to 
respond to the medication switch or addition of CBT, were followed while receiving 
naturalistic (non-protocol directed) care (re-assessment at weeks 48 and 72). The cumulative 
remission rate at 24 weeks was 39% (62% of responders to acute 12-week treatment and 
18.3% of non-responders). Nearly 20% of week 12 responders experienced a relapse by 
week 24. Moreover, approximately one quarter of week 24 responders experienced a relapse 
within 48 weeks. Remission rate improved to 61.1% by week 72, though many participants 
had residual symptoms. Continuation of antidepressant treatment for >48 weeks was 
associated with higher remission rates than for patients who discontinued treatment <48 
weeks, although this difference was no longer statistically significant by approximately 18 
months. Unlike in TADS, CBT was not associated with a longer term impact on remission or 
non-relapse33 but the “dose” of CBT treatment was relatively low and those not initially 
assigned to CBT were able to pursue this during the open treatment phase. This complicates 
interpretation, particularly given that subsequent studies have suggested a role of CBT for 
relapse prevention in depressed youth.34,35
Adolescent Depression and Psychotherapy Trial (ADAPT)—The Adolescent 
Depression and Psychotherapy Trial (ADAPT), pragmatic randomized controlled trial of 
combination therapy randomized adolescents (N=208) with moderate to severe MDD who 
failed to respond to a brief initial intervention (>2 sessions focused on an explanation of 
MDD and exploration of recent family and/or peer group conflict) to SSRI monotherapy 
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(primarily fluoxetine) or SSRI+CBT.36 The proportion of participants who reported 
significant improvement increased from 43% at week 12 to 57% at week 28 and SSRI + 
CBT was not superior to SSRI monotherapy at 12 or 28 weeks of treatment. However, 
patients in the ADAPT trial may have had higher depressive symptom burdens that those in 
TADS which may subtend the differences in outcome. Interestingly, in a subgroup analysis 
of the most severely ill participants in TADS, superiority of combined treatment versus 
fluoxetine alone was not observed.36
Other Depression Randomized Controlled Trials with Long-Term Response 
Data—One study of adolescents with MDD who responded to fluoxetine (open-label, 12 
weeks) randomized patients to continue fluoxetine or placebo for 6 months. Relapse was 
significantly more common in patients randomized to placebo than those randomized to 
fluoxetine (69% vs. 42%, N=102, p=0.009) and earlier relapse was observed in those 
patients treated with placebo (8–14 weeks vs. >24 weeks, p<0.006).37 An additional longer-
term study of youth who had responded to acute treatment with sertraline (12 weeks) 
observed that during 24-weeks following the acute treatment phase, sertraline-treated 
patients had higher rates of sustained response compared to placebo (38% vs. 0%, p<0.05) 
during a 52-week double-blinded maintenance treatment period. This study, although well-
designed, was limited by sample size and eo ipso power limitations (e.g., maintenance phase 
included only 22 participants).38 Finally, a 2012 Cochrane review of nine RCTs, evaluated 
relapse and recurrence in pediatric patients with MDD and noted that “antidepressant 
medication reduces the chance of relapse-recurrence in the future” and “limited evidence 
that continued medication is more effective than placebo in preventing the next episode of 
depression once a child or adolescent has initially responded to medication during acute 
phase treatment.” However, the optimal continuation therapy was not determined.
Major Depressive Disorder: Predictors of Recurrence
Recovery from an initial major depressive episode occurs within 1–2 years for most youth; 
however, recurrence is common and frequently occurs 6–12 months following the 
discontinuation of the acute treatment.39 Randomized controlled trials have recently 
suggested predictors of treatment response (e.g., low family conflict, higher socioeconomic 
status, lack of co-occurring anxiety) (Table 1). The evidence for longer-term predictors of 
relapse and recurrence are limited or, in some cases, conflicting (Table 1).
Anxiety Disorders: Current Acute and Long-Term Treatment Recommendations
Although more than a decade old, the AACAP Practice Parameters for the treatment of 
anxiety disorders20 suggest evidence-based psychotherapy (e.g., CBT) as the initial 
treatment for mild anxiety disorders in youth, while SSRIs are recommended for patients 
with (1) moderate to severe anxiety disorders; (2) impairments that limit their ability to 
engage in psychotherapy; and (3) partial response to psychotherapy.20 Following acute 
antidepressant treatment for anxious youth, only one recommendation has addressed the 
duration of treatment. This recommendation consists of an expert opinion paper, more than 
15 years old,40 that recommends antidepressant discontinuation during a low-stress period, 
>1 year following reduction in anxiety or depressive symptoms. However, descriptions of 
relapse and remission, that have been operationalized in MDD, have—at times—been 
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difficult to operationalize with pediatric anxiety disorders. Definitions for such terminology 
in anxiety disorders have adopted terminology specifically for MDD.26 Differences in 
assessment scales and definitions of treatment response and remission are frequently cited as 
a source of variation in findings across studies.15,41
Anxiety Disorders: Evidence for Antidepressant Treatment Duration
Child/Adolescent Anxiety Multimodal Study (CAMS)—The Child/Adolescent 
Anxiety Multimodal Study (CAMS) randomized youth with separation, generalized and/or 
social anxiety disorder (N=488) to: (1) sertraline monotherapy, (2) CBT monotherapy, (3) 
combined sertraline and CBT, and (4) pill placebo.42 After 12 weeks of acute treatment, all 
three treatments were superior to placebo, and combined therapy was associated with a 
response rate of approximately 80% and was superior to either monotherapy (CBT 60% vs. 
sertraline 55%, t=−1.32, p=0.19).4 Participants who had responded to any of the three 
treatment arms during the initial 12 week acute treatment period were followed for a 6-
month maintenance period.43 Similar to TADS, the two monotherapy treatments continued 
to improve. Statistically significant differences for the monotherapies (i.e., sertraline or 
CBT) compared to combined therapy were no longer present by weeks 24 (combined 
treatment vs sertraline p=0.092; combined treatment vs CBT p=0.16; sertraline vs. CBT 
p=0.859) and 36 (combined treatment vs. sertraline p=0.176; combined treatment vs CBT 
p=0.144; sertraline vs. CBT p=0.931). However, when remission was defined as “no longer 
meeting diagnostic criteria for the anxiety disorders under study,” combined therapy 
maintained superiority at week 36 (combined treatment vs. sertraline p<0.005; combined 
treatment vs. CBT p<0.006).43
Child/Adolescent Anxiety Multimodal Extended Long-Term Study (CAMELS)—
The Child/Adolescent Anxiety Multimodal Extended Long-term Study (CAMELS) followed 
a sub-set of CAMS participants for an average of 6.2 years (range: 3.7–9.9 years) following 
CAMS randomization (N=288).41 Nearly half (47%) of CAMELS participants were in 
remission, including 52% of those who responded to acute CAMS treatment and 37.6% of 
those who did not. However, the context of these remission rates is important. Participants 
left university-based care and were treated with community-based care. They were 
monitored at lower frequency, may have had shorter appointment times and may have had 
more conservative dosing and less aggressive management of co-morbid conditions.
Other Longer-Term Trials in Pediatric Anxiety Disorders—One follow up study of 
the Research Units on Pediatric Psychopharmacology Anxiety Study found that 94% of 
those who had previously responded to fluvoxamine during an acute 8-week treatment 
course (N=35) maintained remission status during a 6-month open treatment period.44 
Another extension study of duloxetine showed continued treatment effects at 18 weeks, 
following acute treatment. In this study, improvement in anxiety severity was observed for 
both treatment groups (i.e., patients randomized to placebo followed by open-label 
duloxetine [PBO/DLX] as well as those randomized to duloxetine and then beginning open-
label duloxetine [DLX/DLX]). The probability of achieving remission at Week 28 was 
identical (83%) for the DLX/DLX and PBO/DLX treatment groups.14
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Anxiety Disorders: Predictors of Recurrence
As with MDD in youth, evidence for predictors of relapse and recurrence in pediatric 
anxiety disorders is limited45 and inconclusive. Longer-term studies suggest that children 
and adolescents who develop anxiety disorders are more likely to have persistent symptoms 
if the initial pathology is more severe or more functionally disabling, and even if the initial 
disorder remits, are more likely to develop new anxiety disorders or comorbidities. One 
study examined long-term (>2 years) outcomes (e.g., remission status, anxiety severity, 
global functioning) in anxious children and adolescents following treatment.41 This study 
involved 59% of CAMS participants; patients were followed for 6.2±1.4 years post-
randomization). At follow-up, nearly half of the sample (47%) had achieved remission, 
which was defined as no longer meeting diagnostic criteria for social anxiety disorder, 
separation anxiety disorder or generalized anxiety disorder (GAD). Responders to acute 
treatment during the 12-week period CAMS were significantly more likely to be in 
remission than non-responders (OR=1.83, 95% CI: 1.08–3.09), and they had less severe 
anxiety (p=0.02) and improved global functioning scores (p=0.02). Other predictors of 
remission status included male sex (OR=1.69, 95% CI: 1.01–2.84), better family 
functioning, and lower baseline anxiety severity. Other variables, which were associated 
with positive outcomes, included higher socioeconomic status (lower anxiety severity, better 
functioning) and the absence of a comorbid externalizing disorder. The absence of attention-
deficit/hyperactivity disorder (ADHD) predicted better functioning at follow-up. Predictors 
of long-term remission/response in pediatric anxiety disorders and depressive disorders are 
shown in Table 1.
DISCUSSION
While the evidence base that informs the optimal duration of treatment for pediatric patients 
with depressive and anxiety disorders significantly lags the data from adult studies, several 
studies that examine relapse as well as open-label continuation and some follow-up studies 
may enable clinicians to make informed recommendations regarding the duration of 
treatment. However, in discussing these studies the goal of treatment—remission—should be 
emphasized. For depressive disorders, current data suggest high and sustained remission 
rates associated with longer treatment durations (e.g., approximately 9–12 months).29,33,37 
One study reported a lower recurrence rate with a 52-week maintenance phase38 compared 
to discontinuation prior to 12 months, the current data support acute antidepressant treatment 
for 6–12 months as an initial strategy for pediatric patients with MDD. By contrast, the 
anxiety literature suggests that the salutary effects of SSRI treatment—regardless of whether 
administered with CBT—are robust at 9 months while other open-label extension studies of 
antidepressants in anxious youth generally suggest similar findings at 6–7 months.14,44 
However, based on a double-blinded antidepressant discontinuation study in adults with 
GAD that suggests that 12 months of treatment (relative to 6 months of treatment) halved the 
relapse rate,46 many clinicians treating anxious youth treat for 12 months rather than 6 
months. Regardless of whether optimal treatment should be for 6–12 months, it is important 
for clinicians to bear in mind that there is no evidence suggesting harm from long-term SSRI 
treatment in the absence of problematic side effects. Though these approaches have not been 
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systematically evaluated in the context of an adaptive design trial, clinicians would do well 
to tailor antidepressant treatment duration based on risk factors for poor prognosis (Table 1).
When antidepressants are to be discontinued, some data47 and expert opinion40 suggest that 
the timing of antidepressant discontinuation should be considered with regard to the 
adolescent’s psychosocial milieu. Shamseddeen and colleagues demonstrated that 
adolescents who end treatment during summer vacation were nearly twice as likely to 
demonstrate adequate treatment response.47 Thus, clinicians should consider planning 
discontinuation of antidepressant treatment during lower stress periods, recognizing the 
importance of incorporating non-disease state dependent factors (e.g., school, separation-
related events) into the antidepressant discontinuation approach. However, clinicians should 
be reminded that for the anxious or depressed child some “low stress periods” for healthy 
youth (e.g., family vacations, summer camp) may be suffused with stress and anxiety that 
could be mistakenly attributed to medication discontinuation.
An important clinical consideration with regard to the duration of psychopharmacologic 
treatment in youth with both MDD and anxiety disorders is the type, frequency and duration 
of concurrent psychotherapeutic treatment. Long-term data in youth with MDD and anxiety 
disorders suggest more rapid improvement associated with combined therapy (i.e., SSRI + 
psychotherapy) relative to antidepressant treatment or psychotherapy alone.15,48 A patient 
who has successfully engaged in psychotherapy during the course of pharmacologic 
treatment or a patient with a more rapid response to acute treatment (more likely with 
combined treatment) might require a briefer psychopharmacologic intervention. However, 
no prospective, randomized controlled trials have evaluated this possibility.
While debate remains regarding the optimal duration of antidepressant treatment for youth 
with MDD or anxiety disorders, the overarching goal of treatment is obvious: remission. 
Any discussion regarding treatment discontinuation is predicated on the patient having 
achieved remission of depressive or anxiety symptoms; remission status indicates clinical 
relief is linked to functional recovery.33 If remission is not achieved with acute treatment 
with either antidepressant monotherapy or antidepressant treatment paired with 
psychotherapy, clinicians should consider changing antidepressants. Such a change should 
not be delayed excessively in hopes of a late response to the initial SSRI (unlikely after an 
initial 8 week treatment period.49 Moreover a switch in SSRI among non-responders has 
been associated with benefit.32,44 In fact, the results of the TORDIA study remind clinicians 
that, following a switch in antidepressant, “eventual remission is evident within the first 6 
weeks in many, suggesting that earlier intervention among non-responders could be 
important.”39
In sum, 9–12 months of SSRI treatment is recommended for pediatric patients with MDD. 
For children and adolescents with generalized, separation and social anxiety disorders, 6–9 
months of SSRI treatment may be sufficient. Many clinicians extend treatment to 12 months 
based on extrapolation of data from adults with anxiety disorders. Such extended treatment 
periods may decrease the risk of long-term morbidity and recurrence; however, the goal of 
treatment is ultimately remission, rather than duration of antidepressant pharmacotherapy.
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Figure 1. Definitions of disease course in children and adolescents with major depressive 
disorder
Definitions are operationalized from studies of the course of MDD in adults (Frank et al. 
1991).
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Table 1
Factors associated with a lower likelihood of response and/or remission in the long-term treatment of MDD 
and anxiety disorders in children and adolescents.
Major Depressive Disorder Anxiety Disorders
More prior depressive episodes (Kovacs et al.1984)
Residual symptoms after treatment (in adults) Greater family levels of expressed 
emotion (Asarnow 1993)
Perceived family conflict (Birmaher et al. 2000, Goodyer et al. 2002)
Non-response to acute therapy (Survey of Outcomes Following Treatment for 
Adolescent Depression Study, unpublished)
Female sex (Survey of Outcomes Following Treatment for Adolescent Depression 
Study, unpublished)
Older age (Ginsburg et al.2011)
Female sex (Ginsburg, et al. 2014)
Minority status (Ginsburg et al. 2011)
Baseline symptom severity Ginsburg et al. 2011 and 2014
Lower socioeconomic status (Ginsburg et al. 2014)
Co-occurring internalizing disorder (Ginsburg et al. 2011
Social anxiety disorder(Ginsburg et al. 2011)
Greater negative life events (Gibby et al. 2017)
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